Japenese pharmaceutical company Takeda may buy its Swiss rival Nycomed, the European Commission said on 2 August.
The Commission says it has cleared the merger because the combined market of Takeda and Nycomed in Austria, Germany and Italy, is not very high, so the merger would not impede competition significantly.
This article is only available to Research Professional News subscribers or Pivot-RP users.
If you are a Research Professional News subscriber you can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.